The Research Behind Serrapeptase

Serrapeptase (also called serratiopeptidase) is a proteolytic enzyme — a protein-digesting enzyme — originally isolated from Serratia species bacteria found in the gut of the silkworm. It belongs to a broader class of metalloprotease enzymes studied for their ability to break down peptide bonds in proteins, and it has been produced commercially for decades via bacterial fermentation for use as a dietary and pharmaceutical ingredient in a number of countries.1

The published literature on serrapeptase spans several decades and includes laboratory characterization of its enzymatic activity, along with a body of clinical research — of varying size and methodological rigor — examining its use as an oral enzyme therapy, most often in the context of postoperative swelling and inflammatory conditions. Systematic reviews of this literature have generally noted that while a number of individual trials report positive findings, the overall evidence base is uneven in study size, design, and reporting quality.1

This section describes serrapeptase as an ingredient studied in the general scientific literature. It is not a claim about iSerra specifically, and no statement here should be read as describing an outcome iSerra itself has been shown to produce.

Proteolytic enzymes, as a category, are structurally vulnerable to the stomach's low pH and to digestive proteases — conditions that can denature an enzyme or cleave it before it reaches the small intestine. This is a general pharmaceutical formulation problem, not one specific to serrapeptase: it's the same reason many enzyme and peptide-based oral products are formulated with protective delivery systems rather than as simple immediate-release tablets or capsules.

Enteric coatings and delayed-release capsule shells are a widely studied approach to this problem. They are designed to resist dissolution in the acidic gastric environment and to disintegrate instead in the higher-pH environment of the small intestine, using that site-specific pH shift as the release trigger. This is general pharmaceutical-sciences background on why such formulations are discussed for acid-sensitive proteolytic enzymes as a category — formulation rationale, not a specific efficacy claim.

Declared specification: ≥250,000 SPU per capsule. Measured result: 292,327 SPU.

This is Lot 6798's own real, documented assay result — not a guarantee of what any other lot, past or future, will measure. Every released lot is assayed and documented on its own terms; see Section 4 to look up a specific bottle's own result.

Bilamex™ Dual-Phase Delivery combines two independent protective layers. The outer layer is a delayed-release capsule shell, formulated to resist breakdown in the low-pH gastric environment and to disintegrate instead once it reaches the higher-pH environment of the small intestine — the pH shift between stomach and intestine is the trigger the shell is designed to respond to, not time elapsed alone.

This resist-then-release behavior is an example of pH-dependent solubility, a widely used and well-characterized approach in delayed-release capsule formulation generally: the shell material is chosen to stay insoluble in the stomach's low-pH environment and to become soluble once it reaches the higher-pH environment of the small intestine, so the pH shift itself — not elapsed time — is what triggers release. This is a general mechanism used across delayed-release capsule technology, not a description of the specific chemistry of iSerra's own shell formulation.

Inside that shell, the enzyme is not loose powder but is carried in individually coated pellets — each pellet carrying its own protective coating. This gives the enzyme a second, independent barrier even after the outer shell opens: rather than the full dose being exposed all at once at a single point, the coated-pellet format is intended to help moderate exposure as the pellets disperse and their coatings break down.

The two stages function in sequence, not redundantly: the capsule shell is the first line of protection through the stomach, and the pellet coatings are the second line of protection once the shell has opened, as material continues to disperse through the intestine.

Section 1 describes proteolytic enzymes as a category being vulnerable to gastric acid and digestive proteases — the general reason enteric and delayed-release formulations are studied for this class of ingredient. Serrapeptase specifically is a protein-digesting enzyme, so an unprotected dose is exposed to exactly the kind of harsh, acidic, protease-rich environment that class of ingredient is generally studied as being vulnerable to.

Bilamex™ is iSerra's specific engineering response to that general formulation problem: staged protection at both the capsule level and the individual-pellet level, designed to help the enzyme reach the intestine before its outer protective layers give way.

Delayed-release capsule performance is evaluated using USP <2040>, the United States Pharmacopeia's disintegration-testing standard for delayed-release (enteric) dosage forms. The test exposes finished capsules to a simulated gastric-phase medium for a defined period, then transfers them to a simulated intestinal-phase medium, recording whether and when disintegration occurs in each phase. It is the relevant standard because it evaluates the finished, whole capsule under conditions modeled on the same gastric-to-intestinal transition the formulation is designed around — not a proxy test on the raw enzyme alone.

Results reflect Lot 6798 testing — one documented lot's result, per the same scope note in Section 2.

References

This literature concerns serrapeptase as an ingredient and does not establish a specific health outcome for iSerra.